Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Nature Medicine|February 11, 2022
Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trialRolando Pajon, Yamuna D Paila, Bethany Girard, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 20, 2023
A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM)Marissa Wilck, Oliver A Cornely, Catherine Cordonnier, et al.
The Journal of Antimicrobial Chemotherapy|September 30, 2017
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal diseaseOliver A Cornely, Michael N Robertson, Shariq Haider, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 10, 2020
A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory TractFrancisco M Marty, Roy F Chemaly, Kathleen M Mullane, et al.
The New England Journal of Medicine|December 7, 2017
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell TransplantationFrancisco M Marty, Per Ljungman, Roy F Chemaly, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 19, 2013
Histoplasmosis after solid organ transplantMaha Assi, Stanley Martin, L Joseph Wheat, et al.
Lancet (London, England)|June 2, 2018
Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trialDrew J Winston, Kathleen M Mullane, Oliver A Cornely, et al.
The New England Journal of Medicine|May 28, 2020
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19Jason D Goldman, David C B Lye, David S Hui, et al.
Open Forum Infectious Diseases|July 20, 2021
Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day MortalitySusan A Olender, Theresa L Walunas, Esteban Martinez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 4, 2019
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant RecipientsRoy F Chemaly, Sanjeet S Dadwal, Anne Bergeron, et al.
Pageof 5